Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
Triple meeting 2024 – Aktis radiotherapy heads for the clinic
AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.
Triple meeting 2024 – Tyra’s targeted FGFR3 push
The company reckons it’s got what it takes to hit the right member of the FGFR family.
Triple meeting 2024 – Zai Lab impresses in small cell
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
Triple meeting 2024 – plenary focus
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
